In recent years，sodium-glucose co-transport 2（SGLT2） inhibitors become a hot topic in diabetes mellitus research be－cause of their unique mechanism. SGLT2 inhibitors not only function on controlling plasma glucose level and HbA1c，but also have some extra therapeutic benefits，for example，reducing the body weight，lowering blood pressure and serum lipids，improving insulin resistance，etc.，indicating a potential protective action on diabetic nephropathy. Compared with the blockade of the RAAS，a classic therapy for diabetic nephropathy in recent years，SGLT2 inhibitors may ameliorate renal end points，leading to a sustainable renal function and a decrease in albuminuria. Thus，SGLT2 inhibitors may be used to improve the long-term outcomes of diabetic nephro-pathy，and grows to be a therapy for diabetic nephropathy.